Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...

The Danish government and the foundation behind Novo Nordisk A/S will invest €80 million ($93 million) in a Microsoft-powered quantum computer to boost technological development in the Nordic ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the drugmaker in a more vulnerable position when rival Eli ...

Novo Nordisk NOVO.B 1.19% plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.

Pharma giant Novo Nordisk announced that it is collaborating with WeightWatchers to offer Wegovy through NovoCare Pharmacy, effective July 1. Through the partnership, WeightWatchers' telehealth ...

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1.

Novo Nordisk is partnering with WeightWatchers to offer consumers access to Wegovy after it abruptly ended its collaboration with Hims & Hers.

Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical giant that is a key player in the weight loss drug market. The firm’s shares have lost 15.7% year-to-date.

Novo Nordisk is under fire over a Spanish obesity awareness campaign. After the campaign stirred up controversy, the Spanish ministry of health wrote to the drugmaker about a possible violation of ...

Novo Nordisk is ending its partnership with Hims & Hers due to concerns over its practices related to compounded GLP-1s.

Novo Nordisk ends collaboration with Hims & Hers for discounted weight loss meds Novo Nordisk and Hims & Hers just announced a partnership in April.